non glp 1 oral medications Foundayo (orforglipron) – First Non-Peptide GLP-1 RA FDA-approved April 2026 for chronic weight management. Once-daily tablet with no fasting requirement, stepwise dosing up to 17.2 mg, and meaningful weight reduction in Found Health's GLP-1 Review: Real

Official supply shortages persisted for most of 2024, as surging demand for AOMs continued to outstrip product supply, despite limited reimbursement, which presented an opportunity quickly seized upon by U.S

Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Notwithstanding the buzz surrounding the novel weight loss treatments, which is vividly playing out on social media and beyond, capturing this commercial opportunity will still require an orderly, rigorous approach to create and shape a new market

As their popularity continues to rise, employers face a unique set of opportunities and challenges, particularly regarding cost management and employee wellbeing

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may have a welcome benefit in addition to weight loss and glycemic control, with new data pre...

We are in your corner with a line of vitafusion vitamins and supplements to support a variety of needs